董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean Stalfort | 男 | Director | 56 | 未披露 | 未持股 | 2025-12-26 |
| Jayson Rieger | 男 | Director,President and Chief Executive Officer | 50 | 未披露 | 未持股 | 2025-12-26 |
| Mark Prygocki | 男 | Director | 59 | 未披露 | 未持股 | 2025-12-26 |
| Diem Nguyen | 女 | Director | 54 | 未披露 | 未持股 | 2025-12-26 |
| Gavin Corcoran | 男 | Director | -- | 未披露 | 未持股 | 2025-12-26 |
| Lawrence Eichenfield | 男 | Director | -- | 未披露 | 未持股 | 2025-12-26 |
| Charles Frantzreb | 男 | Director | 36 | 未披露 | 未持股 | 2025-12-26 |
| Paul B. Manning | 男 | Chairman of the Board | 70 | 未披露 | 未持股 | 2025-12-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jayson Rieger | 男 | Director,President and Chief Executive Officer | 50 | 未披露 | 未持股 | 2025-12-26 |
| Noah Rosenberg | 男 | Chief Medical Officer | -- | 未披露 | 未持股 | 2025-12-26 |
| David Zawitz | 男 | Chief Operating Officer | -- | 未披露 | 未持股 | 2025-12-26 |
| John J. Kirby | 男 | Interim Chief Financial Officer | 54 | 未披露 | 未持股 | 2025-12-26 |
董事简历
中英对照 | 中文 | 英文- Sean Stalfort
-
Sean Stalfort自2016年9月以来一直担任我们的董事会成员。Stalfort自2010年5月起担任PBM Capital Group，LLC（一家私募股权投资公司，从事梦百合和生命科学相关公司的投资业务）合伙人。在加入PBM Capital Group，LLC之前，Stalfort先生是PBM产品新业务开发/并购的执行Vice President。Stalfort先生也是Octagon Partners和Octagon Finance的创始合伙人，这是一家历史性的税收抵免房地产公司。Stalfort先生是几家私营梦百合公司的董事。Stalfort先生还于2016年4月至2016年12月担任我们的总裁。Stalfort先生在布朗大学（Brown University）获得商业经济与政治学学士学位。
Sean Stalfort has served as a member of our board of directors since October 2018. Mr. Stalfort is President of PBM Capital Group, LLC, a private equity and venture capital investment firm in the business of investing in healthcare and life-science related companies, and has worked at PBM Capital since 2010.Mr. Stalfort is a director of Verrica Pharmaceuticals, Inc., a biopharmaceutical company, and he previously served as a director of Dova Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining PBM Capital, he was the executive vice president for new business development/M&A for PBM Products. Mr. Stalfort is also a founding partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Mr. Stalfort received a B.A. in business economics and political science from Brown University. - Sean Stalfort自2016年9月以来一直担任我们的董事会成员。Stalfort自2010年5月起担任PBM Capital Group，LLC（一家私募股权投资公司，从事梦百合和生命科学相关公司的投资业务）合伙人。在加入PBM Capital Group，LLC之前，Stalfort先生是PBM产品新业务开发/并购的执行Vice President。Stalfort先生也是Octagon Partners和Octagon Finance的创始合伙人，这是一家历史性的税收抵免房地产公司。Stalfort先生是几家私营梦百合公司的董事。Stalfort先生还于2016年4月至2016年12月担任我们的总裁。Stalfort先生在布朗大学（Brown University）获得商业经济与政治学学士学位。
- Sean Stalfort has served as a member of our board of directors since October 2018. Mr. Stalfort is President of PBM Capital Group, LLC, a private equity and venture capital investment firm in the business of investing in healthcare and life-science related companies, and has worked at PBM Capital since 2010.Mr. Stalfort is a director of Verrica Pharmaceuticals, Inc., a biopharmaceutical company, and he previously served as a director of Dova Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining PBM Capital, he was the executive vice president for new business development/M&A for PBM Products. Mr. Stalfort is also a founding partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Mr. Stalfort received a B.A. in business economics and political science from Brown University.
- Jayson Rieger
-
Jayson Rieger自2015年12月以来一直担任我们的董事会成员。Rieger博士自2014年以来一直担任PBM Capital Group的负责人，在那里他管理新的投资评估，交易采购，并为投资组合公司提供技术和运营业务支持。在PBM Capital任职之前，Rieger博士从2012年到2013年担任Intrexon Corporation公司（一家合成生物学公司）的公司高级副总裁和人类治疗部门总裁。从2008年到2011年被Forest Labs收购，Rieger博士还担任ClinicalData，Inc.研究与弗吉尼亚运营的Vice President。他此前也曾担任Adenosine Therapeutics公司的铅开发Vice President（从2002年到2008年被Clinical Data公司收购）。Rieger博士在弗吉尼亚大学（University of Virginia）化学系获得博士学位，在达顿商学院（Darden Business School）获得工商管理硕士学位，在罗林斯学院（Rollins College）获得学士学位。
Jayson Rieger has served as a member of board of directors since December 2015. Dr. Rieger has been a principal at PBM Capital Group since 2014 where he manages new investment evaluation, deal sourcing, and provides technical and operational business support for portfolio companies. Prior to his tenure at PBM Capital, Dr. Rieger served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, a synthetic biology company, from 2012 to 2013. Dr. Rieger also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc. from 2008 to its acquisition by Forest Labs in 2011. He also previously held the role of Vice President of Lead Development at Adenosine Therapeutics, LLC from 2002 until it was acquired by Clinical Data in 2008. Dr. Rieger received his Ph.D. from the University of Virginia Dept. of Chemistry, MBA from the Darden Business School and B.A. from Rollins College. - Jayson Rieger自2015年12月以来一直担任我们的董事会成员。Rieger博士自2014年以来一直担任PBM Capital Group的负责人，在那里他管理新的投资评估，交易采购，并为投资组合公司提供技术和运营业务支持。在PBM Capital任职之前，Rieger博士从2012年到2013年担任Intrexon Corporation公司（一家合成生物学公司）的公司高级副总裁和人类治疗部门总裁。从2008年到2011年被Forest Labs收购，Rieger博士还担任ClinicalData，Inc.研究与弗吉尼亚运营的Vice President。他此前也曾担任Adenosine Therapeutics公司的铅开发Vice President（从2002年到2008年被Clinical Data公司收购）。Rieger博士在弗吉尼亚大学（University of Virginia）化学系获得博士学位，在达顿商学院（Darden Business School）获得工商管理硕士学位，在罗林斯学院（Rollins College）获得学士学位。
- Jayson Rieger has served as a member of board of directors since December 2015. Dr. Rieger has been a principal at PBM Capital Group since 2014 where he manages new investment evaluation, deal sourcing, and provides technical and operational business support for portfolio companies. Prior to his tenure at PBM Capital, Dr. Rieger served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, a synthetic biology company, from 2012 to 2013. Dr. Rieger also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc. from 2008 to its acquisition by Forest Labs in 2011. He also previously held the role of Vice President of Lead Development at Adenosine Therapeutics, LLC from 2002 until it was acquired by Clinical Data in 2008. Dr. Rieger received his Ph.D. from the University of Virginia Dept. of Chemistry, MBA from the Darden Business School and B.A. from Rollins College.
- Mark Prygocki
-
Mark Prygocki自2018年5月以来一直担任我们的董事会成员。自2017年1月以来，他一直担任Illulis Pharmaceuticals，Inc.（一家私人持有的生物开发公司）的总裁，首席执行官和董事会成员。在加入Illustris之前，Prygocki先生在生物制药公司Medicis Pharmaceutical Corporation工作了20多年，并于2010年至2012年12月担任总裁。在此之前，Prygocki先生曾在Medicis担任多个高级职位，包括首席运营官、执行Vice President以及首席财务官和财务主管。自2012年12月以来，Prygocki先生通过其咨询公司担任制药和零售行业的顾问。Prygocki’；先生先前的经验包括在花旗集团（Citigroup）（一家投资银行公司）监管报告部门工作，以及在安永会计师事务所（Ernst&Young，LLP）审计部门工作数年。Prygocki先生目前在ClarusTherapeutics，Inc.董事会任职，并担任其审计委员会主席。Prygocki先生还在过去五年中担任RevanceTherapeutics，Inc.董事会成员。他获得美国注册会计师协会认证。Prygocki先生任职于Whispering Hope Ranch Foundation的董事会，这是一家帮助有特殊需要的儿童的非营利组织。Prygocki先生拥有佩斯大学（Pace University）会计学学士学位。
Mark Prygocki has served as a member of board of directors since May 2018. Since January 2017 he has served as President, Chief Executive Officer and been a member of the Board of Directors of Illustris Pharmaceuticals, Inc., a privately held bio-development company. Prior to joining Illustris, Mr. Prygocki worked at Medicis Pharmaceutical Corporation, a biopharmaceutical company, for more than 20 years and served as President from 2010 to December 2012. Prior to that, Mr. Prygocki held several senior-level positions at Medicis, including Chief Operating Officer, Executive Vice President, and Chief Financial Officer and Treasurer. Since December 2012 Mr. Prygocki has served as a consultant to the pharmaceutical and retail industries through his consulting company. Mr. Prygocki's previous experience includes work at Citigroup, an investment banking firm, in the regulatory reporting division and several years in the audit department of Ernst & Young, LLP. Mr. Prygocki currently serves on the board of directors of Clarus Therapeutics, Inc. and is Chairman of its audit committee. Mr. Prygocki also served on the board of directors of Revance Therapeutics, Inc. within the last five years. He is certified by the American Institute of Certified Public Accountants. Mr. Prygocki serves on the board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs. Mr. Prygocki holds a B.S. in accounting from Pace University. - Mark Prygocki自2018年5月以来一直担任我们的董事会成员。自2017年1月以来，他一直担任Illulis Pharmaceuticals，Inc.（一家私人持有的生物开发公司）的总裁，首席执行官和董事会成员。在加入Illustris之前，Prygocki先生在生物制药公司Medicis Pharmaceutical Corporation工作了20多年，并于2010年至2012年12月担任总裁。在此之前，Prygocki先生曾在Medicis担任多个高级职位，包括首席运营官、执行Vice President以及首席财务官和财务主管。自2012年12月以来，Prygocki先生通过其咨询公司担任制药和零售行业的顾问。Prygocki’；先生先前的经验包括在花旗集团（Citigroup）（一家投资银行公司）监管报告部门工作，以及在安永会计师事务所（Ernst&Young，LLP）审计部门工作数年。Prygocki先生目前在ClarusTherapeutics，Inc.董事会任职，并担任其审计委员会主席。Prygocki先生还在过去五年中担任RevanceTherapeutics，Inc.董事会成员。他获得美国注册会计师协会认证。Prygocki先生任职于Whispering Hope Ranch Foundation的董事会，这是一家帮助有特殊需要的儿童的非营利组织。Prygocki先生拥有佩斯大学（Pace University）会计学学士学位。
- Mark Prygocki has served as a member of board of directors since May 2018. Since January 2017 he has served as President, Chief Executive Officer and been a member of the Board of Directors of Illustris Pharmaceuticals, Inc., a privately held bio-development company. Prior to joining Illustris, Mr. Prygocki worked at Medicis Pharmaceutical Corporation, a biopharmaceutical company, for more than 20 years and served as President from 2010 to December 2012. Prior to that, Mr. Prygocki held several senior-level positions at Medicis, including Chief Operating Officer, Executive Vice President, and Chief Financial Officer and Treasurer. Since December 2012 Mr. Prygocki has served as a consultant to the pharmaceutical and retail industries through his consulting company. Mr. Prygocki's previous experience includes work at Citigroup, an investment banking firm, in the regulatory reporting division and several years in the audit department of Ernst & Young, LLP. Mr. Prygocki currently serves on the board of directors of Clarus Therapeutics, Inc. and is Chairman of its audit committee. Mr. Prygocki also served on the board of directors of Revance Therapeutics, Inc. within the last five years. He is certified by the American Institute of Certified Public Accountants. Mr. Prygocki serves on the board of Whispering Hope Ranch Foundation, a non-profit organization that assists children with special needs. Mr. Prygocki holds a B.S. in accounting from Pace University.
- Diem Nguyen
-
Diem Nguyen将在本注册声明生效后担任我们的董事会成员。Nguyen博士是Xalud Therapeutics（一家私人生物技术公司，由PBM Capital持有多数股权）的首席执行官和董事会成员。此前，她曾担任PPD（提供药物开发服务的全球领先临床研究机构）的执行副总裁（从2018年4月到2020年4月）。Nguyen博士自2008年起在辉瑞公司担任多个领导职务，最后一次担任Pfizer Essential Health的美洲地区全球总裁（从2017年1月到2018年3月）。Nguyen博士是Verrica PharmaceuticalsInc.的董事纳斯达克:VRCA和费城儿童医院。她在弗吉尼亚大学（University of Virginia）获得化学学士学位，专长于生物化学，生物化学和分子遗传学博士学位，并在弗吉尼亚大学达顿商学院（University of Virginia）获得一般管理工商管理硕士学位。
Diem Nguyen,has served as a member of Candel's board of directors since July 2021. Since October 2020, Dr. Nguyen has been the Chief Executive Officer and member of the board of directors of Xalud Therapeutics, Inc., a private biotechnology company, which is majority-owned by PBM Capital. Previously, Dr. Nguyen was the Executive Vice President of PPD, Inc. a leading global clinical research organization providing drug development services, a position she held from April 2018 to April 2020. Since 2008, Dr. Nguyen has held various leadership roles at Pfizer Inc. (NYSE: PFE), last serving as Global President, Americas of Pfizer Essential Health from January 2017 to March 2018. Dr. Nguyen is a director at Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), Vitara Biomedical, Inc. and Children's Hospital of Philadelphia. She received a B.A. in Chemistry with Specialization in Biochemistry and a Ph.D. in Biochemistry and Molecular Genetics from the University of Virginia, and an M.B.A. in General Management from the University of Virginia's Darden Graduate School of Business Administration. - Diem Nguyen将在本注册声明生效后担任我们的董事会成员。Nguyen博士是Xalud Therapeutics（一家私人生物技术公司，由PBM Capital持有多数股权）的首席执行官和董事会成员。此前，她曾担任PPD（提供药物开发服务的全球领先临床研究机构）的执行副总裁（从2018年4月到2020年4月）。Nguyen博士自2008年起在辉瑞公司担任多个领导职务，最后一次担任Pfizer Essential Health的美洲地区全球总裁（从2017年1月到2018年3月）。Nguyen博士是Verrica PharmaceuticalsInc.的董事纳斯达克:VRCA和费城儿童医院。她在弗吉尼亚大学（University of Virginia）获得化学学士学位，专长于生物化学，生物化学和分子遗传学博士学位，并在弗吉尼亚大学达顿商学院（University of Virginia）获得一般管理工商管理硕士学位。
- Diem Nguyen,has served as a member of Candel's board of directors since July 2021. Since October 2020, Dr. Nguyen has been the Chief Executive Officer and member of the board of directors of Xalud Therapeutics, Inc., a private biotechnology company, which is majority-owned by PBM Capital. Previously, Dr. Nguyen was the Executive Vice President of PPD, Inc. a leading global clinical research organization providing drug development services, a position she held from April 2018 to April 2020. Since 2008, Dr. Nguyen has held various leadership roles at Pfizer Inc. (NYSE: PFE), last serving as Global President, Americas of Pfizer Essential Health from January 2017 to March 2018. Dr. Nguyen is a director at Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), Vitara Biomedical, Inc. and Children's Hospital of Philadelphia. She received a B.A. in Chemistry with Specialization in Biochemistry and a Ph.D. in Biochemistry and Molecular Genetics from the University of Virginia, and an M.B.A. in General Management from the University of Virginia's Darden Graduate School of Business Administration.
- Gavin Corcoran
-
Gavin Corcoran，自2025年3月起担任Verrica Pharmaceuticals Inc.董事会成员。Corcoran博士自2021年11月起担任Formation Bio的首席开发官。Corcoran博士此前曾于2018年至2021年11月担任Sio Gene Therapies, Inc.（原名Axovant）的首席研发官，2015年至2018年担任Allergan plc的首席医疗官，2014年至2015年担任Actavis plc的首席医疗官，并于2011年12月至2014年6月担任Forest Laboratories，Inc.的全球药物开发执行副总裁，此前该公司于2014年被Actavis收购Forest Laboratories，Inc.。他在南非威特沃特斯兰德大学获得工商管理硕士学位，并在圣安东尼奥的得克萨斯大学健康科学中心完成了内科和传染病的临床训练。
Gavin Corcoran,has served as a member of Verrica Pharmaceuticals Inc. Board of Directors since March 2025. Dr. Corcoran has served as the Chief Development Officer of Formation Bio since November 2021. Dr. Corcoran previously served as the Chief Research and Development Officer of Sio Gene Therapies, Inc. (formerly known as Axovant) from 2018 to November 2021, Chief Medical Officer of Allergan plc from 2015 to 2018, Chief Medical Officer of Actavis plc from 2014 to 2015 and Executive Vice President for Global Medicines Development at Forest Laboratories, Inc. from December 2011 to June 2014, prior to the acquisition of Forest Laboratories, Inc. by Actavis in 2014. He received his M.B. B.Ch. from the University of Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio. - Gavin Corcoran，自2025年3月起担任Verrica Pharmaceuticals Inc.董事会成员。Corcoran博士自2021年11月起担任Formation Bio的首席开发官。Corcoran博士此前曾于2018年至2021年11月担任Sio Gene Therapies, Inc.（原名Axovant）的首席研发官，2015年至2018年担任Allergan plc的首席医疗官，2014年至2015年担任Actavis plc的首席医疗官，并于2011年12月至2014年6月担任Forest Laboratories，Inc.的全球药物开发执行副总裁，此前该公司于2014年被Actavis收购Forest Laboratories，Inc.。他在南非威特沃特斯兰德大学获得工商管理硕士学位，并在圣安东尼奥的得克萨斯大学健康科学中心完成了内科和传染病的临床训练。
- Gavin Corcoran,has served as a member of Verrica Pharmaceuticals Inc. Board of Directors since March 2025. Dr. Corcoran has served as the Chief Development Officer of Formation Bio since November 2021. Dr. Corcoran previously served as the Chief Research and Development Officer of Sio Gene Therapies, Inc. (formerly known as Axovant) from 2018 to November 2021, Chief Medical Officer of Allergan plc from 2015 to 2018, Chief Medical Officer of Actavis plc from 2014 to 2015 and Executive Vice President for Global Medicines Development at Forest Laboratories, Inc. from December 2011 to June 2014, prior to the acquisition of Forest Laboratories, Inc. by Actavis in 2014. He received his M.B. B.Ch. from the University of Witwatersrand in South Africa and completed his clinical training in internal medicine and infectious diseases at the University of Texas Health Science Center at San Antonio.
- Lawrence Eichenfield
-
Lawrence Eichenfield，自2020年7月起担任Verrica Pharmaceuticals Inc.董事会成员。Eichenfield博士自1991年起担任圣地亚哥Rady儿童医院儿科和青少年皮肤科主任，自2009年起担任加州大学圣地亚哥分校医学院皮肤科副主任和皮肤科和儿科教授。他曾于2002-3年担任儿科皮肤病学会主席，2005年至2009年担任美国皮肤病学会董事会成员，并担任美国皮肤病学会第69届年会主席。他是合作研究网络儿科皮肤病学Research Alliance（PEDRA）的联合创始人和前任主席，也是美国痤疮和酒渣鼻协会的创始董事会成员和前任主席。曾任《儿科皮肤病学》主编12年，担任多个期刊的编委。Eichenfield博士于2020年6月至2024年9月期间担任Forte Biosciences董事会成员。Eichenfield博士在纽约西奈山医学院获得医学学位，曾是费城儿童医院的儿科住院医师和首席住院医师，并在宾夕法尼亚大学的医院完成了皮肤病学培训。他在儿科、皮肤科和儿科皮肤科获得董事会认证。他曾在医学院期间被授予Alpha Omega Alpha荣誉协会成员，并作为费城儿童医院、加州大学圣地亚哥分校儿科、加州大学圣地亚哥分校皮肤科和圣地亚哥Rady儿童医院多项临床卓越奖和教学奖项的获得者。
Lawrence Eichenfield,has served as a member of Verrica Pharmaceuticals Inc. Board of Directors since July 2020. Dr. Eichenfield has been the chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego since 1991, as well as vice chair of the Department of Dermatology and a professor of dermatology and pediatrics at UC San Diego School of Medicine since 2009. He served as President of the Society for Pediatric Dermatology in 2002-3, on the board of the American Academy of Dermatology from 2005 to 2009, and served as chair for the 69th Annual Meeting of the American Academy of Dermatology. He is a co-Founder and former Chair of the Pediatric Dermatology Research Alliance (PeDRA), a collaborative research network, and a founding board member and past-president of the American Acne and Rosacea Society. He served as Editor-in-Chief of Pediatric Dermatology for 12 years and serves on the editorial boards of multiple journals and periodicals. Dr. Eichenfield served on the board of directors of Forte Biosciences, Inc. from June 2020 to September 2024. Dr. Eichenfield earned his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and chief resident at Children's Hospital of Philadelphia, and completed dermatology training at the hospital of the University of Pennsylvania. He is board certified in pediatrics, dermatology and pediatric dermatology. He has been honored as a member of the Alpha Omega Alpha Honor Society during medical school, and as a recipient of multiple clinical excellence and teaching awards from the Children's Hospital of Philadelphia, UC San Diego Pediatrics, UC San Diego Dermatology and Rady Children's Hospital-San Diego. - Lawrence Eichenfield，自2020年7月起担任Verrica Pharmaceuticals Inc.董事会成员。Eichenfield博士自1991年起担任圣地亚哥Rady儿童医院儿科和青少年皮肤科主任，自2009年起担任加州大学圣地亚哥分校医学院皮肤科副主任和皮肤科和儿科教授。他曾于2002-3年担任儿科皮肤病学会主席，2005年至2009年担任美国皮肤病学会董事会成员，并担任美国皮肤病学会第69届年会主席。他是合作研究网络儿科皮肤病学Research Alliance（PEDRA）的联合创始人和前任主席，也是美国痤疮和酒渣鼻协会的创始董事会成员和前任主席。曾任《儿科皮肤病学》主编12年，担任多个期刊的编委。Eichenfield博士于2020年6月至2024年9月期间担任Forte Biosciences董事会成员。Eichenfield博士在纽约西奈山医学院获得医学学位，曾是费城儿童医院的儿科住院医师和首席住院医师，并在宾夕法尼亚大学的医院完成了皮肤病学培训。他在儿科、皮肤科和儿科皮肤科获得董事会认证。他曾在医学院期间被授予Alpha Omega Alpha荣誉协会成员，并作为费城儿童医院、加州大学圣地亚哥分校儿科、加州大学圣地亚哥分校皮肤科和圣地亚哥Rady儿童医院多项临床卓越奖和教学奖项的获得者。
- Lawrence Eichenfield,has served as a member of Verrica Pharmaceuticals Inc. Board of Directors since July 2020. Dr. Eichenfield has been the chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego since 1991, as well as vice chair of the Department of Dermatology and a professor of dermatology and pediatrics at UC San Diego School of Medicine since 2009. He served as President of the Society for Pediatric Dermatology in 2002-3, on the board of the American Academy of Dermatology from 2005 to 2009, and served as chair for the 69th Annual Meeting of the American Academy of Dermatology. He is a co-Founder and former Chair of the Pediatric Dermatology Research Alliance (PeDRA), a collaborative research network, and a founding board member and past-president of the American Acne and Rosacea Society. He served as Editor-in-Chief of Pediatric Dermatology for 12 years and serves on the editorial boards of multiple journals and periodicals. Dr. Eichenfield served on the board of directors of Forte Biosciences, Inc. from June 2020 to September 2024. Dr. Eichenfield earned his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and chief resident at Children's Hospital of Philadelphia, and completed dermatology training at the hospital of the University of Pennsylvania. He is board certified in pediatrics, dermatology and pediatric dermatology. He has been honored as a member of the Alpha Omega Alpha Honor Society during medical school, and as a recipient of multiple clinical excellence and teaching awards from the Children's Hospital of Philadelphia, UC San Diego Pediatrics, UC San Diego Dermatology and Rady Children's Hospital-San Diego.
- Charles Frantzreb
-
Charles Frantzreb，自2024年12月起担任专注于治疗的投资公司Caligan的合伙人。在加入Caligan之前，Frantzreb博士于2020年至2024年11月期间担任Great Point Partners的高级分析师，该公司是一家专注于医疗保健的多头/空头对冲基金，负责该公司的肿瘤投资。在加入Great Point Partners之前，他于2018年至2020年在Piper Sandler担任股票研究助理。Frantzreb博士在宾夕法尼亚大学获得医学博士学位，在康奈尔大学获得学士学位。
Charles Frantzreb,has served as a Partner at Caligan, a therapeutics-dedicated investment firm, since December 2024. Prior to joining Caligan, Dr. Frantzreb served as a Senior Analyst at Great Point Partners, a healthcare-dedicated long/short hedge fund, from 2020 to November 2024, where he covered oncology investments for the firm. Prior to Great Point Partners, he worked as an equity research associate at Piper Sandler from 2018 to 2020. Dr. Frantzreb earned his M.D. from the University of Pennsylvania and his B.A. from Cornell University. - Charles Frantzreb，自2024年12月起担任专注于治疗的投资公司Caligan的合伙人。在加入Caligan之前，Frantzreb博士于2020年至2024年11月期间担任Great Point Partners的高级分析师，该公司是一家专注于医疗保健的多头/空头对冲基金，负责该公司的肿瘤投资。在加入Great Point Partners之前，他于2018年至2020年在Piper Sandler担任股票研究助理。Frantzreb博士在宾夕法尼亚大学获得医学博士学位，在康奈尔大学获得学士学位。
- Charles Frantzreb,has served as a Partner at Caligan, a therapeutics-dedicated investment firm, since December 2024. Prior to joining Caligan, Dr. Frantzreb served as a Senior Analyst at Great Point Partners, a healthcare-dedicated long/short hedge fund, from 2020 to November 2024, where he covered oncology investments for the firm. Prior to Great Point Partners, he worked as an equity research associate at Piper Sandler from 2018 to 2020. Dr. Frantzreb earned his M.D. from the University of Pennsylvania and his B.A. from Cornell University.
- Paul B. Manning
-
PaulB.Manning自2020年3月以来一直担任我们的董事会成员。Manning先生目前担任PBM Capital Group，LLC的首席执行官，这是一家私募股权投资公司，其业务是投资于梦百合和生命科学相关公司，该公司由他于2010年创立。Manning先生目前担任Verrica PharmaceuticalsInc.公司（一家生物制药公司）董事会主席。此外，他曾于2016年9月至2019年11月担任生物制药公司Dova制药有限公司的董事会成员，并于2014年4月至2018年5月担任基因治疗公司Avexis，Inc.的董事会成员。Manning先生在马萨诸塞大学（University of Massachusetts）获得微生物学学士学位。
Paul B. Manning,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since March 2020. Mr. Manning currently serves as the Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr. Manning has served as interim Chief Executive Officer of SalioGen Therapeutics, Inc., a private biopharmaceutical company, since November 2022. Mr. Manning currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and on the boards of directors of Liquidia Corporation, a publicly traded biopharmaceutical company, and Candel Therapeutics, Inc., a publicly traded biopharmaceutical company. Additionally, he previously served on the boards of directors of Dova Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2016 to November 2019 and AveXis, Inc., a publicly traded gene therapy company, from 2014 to May 2018. Mr. Manning earned a B.S. in microbiology from the University of Massachusetts. - PaulB.Manning自2020年3月以来一直担任我们的董事会成员。Manning先生目前担任PBM Capital Group，LLC的首席执行官，这是一家私募股权投资公司，其业务是投资于梦百合和生命科学相关公司，该公司由他于2010年创立。Manning先生目前担任Verrica PharmaceuticalsInc.公司（一家生物制药公司）董事会主席。此外，他曾于2016年9月至2019年11月担任生物制药公司Dova制药有限公司的董事会成员，并于2014年4月至2018年5月担任基因治疗公司Avexis，Inc.的董事会成员。Manning先生在马萨诸塞大学（University of Massachusetts）获得微生物学学士学位。
- Paul B. Manning,has served as a member of Taysha Gene Therapies, Inc. Board of Directors since March 2020. Mr. Manning currently serves as the Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Mr. Manning has served as interim Chief Executive Officer of SalioGen Therapeutics, Inc., a private biopharmaceutical company, since November 2022. Mr. Manning currently serves as Chairman of the board of directors of Verrica Pharmaceuticals Inc., a publicly traded biopharmaceutical company, and on the boards of directors of Liquidia Corporation, a publicly traded biopharmaceutical company, and Candel Therapeutics, Inc., a publicly traded biopharmaceutical company. Additionally, he previously served on the boards of directors of Dova Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2016 to November 2019 and AveXis, Inc., a publicly traded gene therapy company, from 2014 to May 2018. Mr. Manning earned a B.S. in microbiology from the University of Massachusetts.
高管简历
中英对照 | 中文 | 英文- Jayson Rieger
Jayson Rieger自2015年12月以来一直担任我们的董事会成员。Rieger博士自2014年以来一直担任PBM Capital Group的负责人，在那里他管理新的投资评估，交易采购，并为投资组合公司提供技术和运营业务支持。在PBM Capital任职之前，Rieger博士从2012年到2013年担任Intrexon Corporation公司（一家合成生物学公司）的公司高级副总裁和人类治疗部门总裁。从2008年到2011年被Forest Labs收购，Rieger博士还担任ClinicalData，Inc.研究与弗吉尼亚运营的Vice President。他此前也曾担任Adenosine Therapeutics公司的铅开发Vice President（从2002年到2008年被Clinical Data公司收购）。Rieger博士在弗吉尼亚大学（University of Virginia）化学系获得博士学位，在达顿商学院（Darden Business School）获得工商管理硕士学位，在罗林斯学院（Rollins College）获得学士学位。
Jayson Rieger has served as a member of board of directors since December 2015. Dr. Rieger has been a principal at PBM Capital Group since 2014 where he manages new investment evaluation, deal sourcing, and provides technical and operational business support for portfolio companies. Prior to his tenure at PBM Capital, Dr. Rieger served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, a synthetic biology company, from 2012 to 2013. Dr. Rieger also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc. from 2008 to its acquisition by Forest Labs in 2011. He also previously held the role of Vice President of Lead Development at Adenosine Therapeutics, LLC from 2002 until it was acquired by Clinical Data in 2008. Dr. Rieger received his Ph.D. from the University of Virginia Dept. of Chemistry, MBA from the Darden Business School and B.A. from Rollins College.- Jayson Rieger自2015年12月以来一直担任我们的董事会成员。Rieger博士自2014年以来一直担任PBM Capital Group的负责人，在那里他管理新的投资评估，交易采购，并为投资组合公司提供技术和运营业务支持。在PBM Capital任职之前，Rieger博士从2012年到2013年担任Intrexon Corporation公司（一家合成生物学公司）的公司高级副总裁和人类治疗部门总裁。从2008年到2011年被Forest Labs收购，Rieger博士还担任ClinicalData，Inc.研究与弗吉尼亚运营的Vice President。他此前也曾担任Adenosine Therapeutics公司的铅开发Vice President（从2002年到2008年被Clinical Data公司收购）。Rieger博士在弗吉尼亚大学（University of Virginia）化学系获得博士学位，在达顿商学院（Darden Business School）获得工商管理硕士学位，在罗林斯学院（Rollins College）获得学士学位。
- Jayson Rieger has served as a member of board of directors since December 2015. Dr. Rieger has been a principal at PBM Capital Group since 2014 where he manages new investment evaluation, deal sourcing, and provides technical and operational business support for portfolio companies. Prior to his tenure at PBM Capital, Dr. Rieger served as Corporate Senior Vice President and President of the Human Therapeutics Division at Intrexon Corporation, a synthetic biology company, from 2012 to 2013. Dr. Rieger also served as the Vice President of Research and Virginia Operations for Clinical Data, Inc. from 2008 to its acquisition by Forest Labs in 2011. He also previously held the role of Vice President of Lead Development at Adenosine Therapeutics, LLC from 2002 until it was acquired by Clinical Data in 2008. Dr. Rieger received his Ph.D. from the University of Virginia Dept. of Chemistry, MBA from the Darden Business School and B.A. from Rollins College.
- Noah Rosenberg
Noah Rosenberg，自2025年3月起担任Verrica Pharmaceuticals Inc.首席医疗官。Rosenberg博士此前曾于2022年1月至2025年3月担任BH Clinical Consulting LLC的负责人、2018年至2022年1月担任Travere Therapeutics Therapeutics，Inc.的首席医疗官、2014年至2018年担任Medimetriks Pharmaceuticals，Inc.的首席医疗官、2012年至2014年担任Esperion Therapeutics，Inc.的首席医疗官，并担任越来越重要的职务，最近担任执行医疗总监、CV/代谢负责人，2009年至2012年担任Forest Laboratories，Inc.的临床开发。罗森伯格博士获得了约翰霍普金斯大学自然科学领域专业的学士学位，获得了德雷塞尔大学医学院的医学博士学位，并在纽约大学西奈山医学院完成了内科住院医师实习。
Noah Rosenberg,has served as Verrica Pharmaceuticals Inc. Chief Medical Officer since March 2025. Dr. Rosenberg previously served as Principal of BH Clinical Consulting LLC from January 2022 to March 2025, Chief Medical Officer of Travere Therapeutics, Inc. from 2018 to January 2022, Chief Medical Officer of Medimetriks Pharmaceuticals, Inc. from 2014 to 2018, Chief Medical Officer of Esperion Therapeutics, Inc. from 2012 to 2014, and in roles of increasing responsibility, most recently Executive Medical Director, Head of CV/Metabolism, Clinical Development at Forest Laboratories, Inc. from 2009 to 2012. Dr. Rosenberg earned his B.A. in a natural sciences area major from The Johns Hopkins University, earned his M.D. from the Drexel University College of Medicine and completed a residency in internal medicine at Mount Sinai School of Medicine of New York University.- Noah Rosenberg，自2025年3月起担任Verrica Pharmaceuticals Inc.首席医疗官。Rosenberg博士此前曾于2022年1月至2025年3月担任BH Clinical Consulting LLC的负责人、2018年至2022年1月担任Travere Therapeutics Therapeutics，Inc.的首席医疗官、2014年至2018年担任Medimetriks Pharmaceuticals，Inc.的首席医疗官、2012年至2014年担任Esperion Therapeutics，Inc.的首席医疗官，并担任越来越重要的职务，最近担任执行医疗总监、CV/代谢负责人，2009年至2012年担任Forest Laboratories，Inc.的临床开发。罗森伯格博士获得了约翰霍普金斯大学自然科学领域专业的学士学位，获得了德雷塞尔大学医学院的医学博士学位，并在纽约大学西奈山医学院完成了内科住院医师实习。
- Noah Rosenberg,has served as Verrica Pharmaceuticals Inc. Chief Medical Officer since March 2025. Dr. Rosenberg previously served as Principal of BH Clinical Consulting LLC from January 2022 to March 2025, Chief Medical Officer of Travere Therapeutics, Inc. from 2018 to January 2022, Chief Medical Officer of Medimetriks Pharmaceuticals, Inc. from 2014 to 2018, Chief Medical Officer of Esperion Therapeutics, Inc. from 2012 to 2014, and in roles of increasing responsibility, most recently Executive Medical Director, Head of CV/Metabolism, Clinical Development at Forest Laboratories, Inc. from 2009 to 2012. Dr. Rosenberg earned his B.A. in a natural sciences area major from The Johns Hopkins University, earned his M.D. from the Drexel University College of Medicine and completed a residency in internal medicine at Mount Sinai School of Medicine of New York University.
- David Zawitz
David Zawitz，自2024年12月起担任Verrica Pharmaceuticals Inc.首席运营官。他还自2024年12月起担任PBM Capital的顾问，此前他曾于2021年3月至2024年12月担任PBM Capital的执行副总裁兼秘书，并于2018年开始在PBM Capital的法律部门担任越来越多的职责。在加入PBM Capital之前，Zawitz先生曾于2012年至2018年在CarMax，Inc.担任越来越多的职责，包括最近担任助理总法律顾问和助理秘书，并于2010年至2012年在Bingham McCutchen LLP和2007年至2009年在McKee Nelson LLP担任私人执业律师。Zawitz先生在弗吉尼亚大学获得了商业学士学位，专注于金融和信息技术，并在弗吉尼亚大学法学院获得了法学博士学位。他还是一名CFA包租人。
David Zawitz,has served as Verrica Pharmaceuticals Inc. Chief Operating Officer since December 2024. He has also served as a consultant to PBM Capital since December 2024, after serving as Executive Vice President and Secretary of PBM Capital from March 2021 to December 2024 and following roles of increasing responsibility within PBM Capital's legal department beginning in 2018. Prior to joining PBM Capital, Mr. Zawitz served in roles of increasing responsibility with CarMax, Inc. from 2012 to 2018, including most recently as Assistant General Counsel and Assistant Secretary, and was an attorney in private practice with Bingham McCutchen LLP from 2010 to 2012 and McKee Nelson LLP from 2007 to 2009. Mr. Zawitz earned a B.S.C. in Commerce with concentrations in Finance and Information Technology from the University of Virginia and a J.D. from the University of Virginia School of Law. He is also a CFA charterholder.- David Zawitz，自2024年12月起担任Verrica Pharmaceuticals Inc.首席运营官。他还自2024年12月起担任PBM Capital的顾问，此前他曾于2021年3月至2024年12月担任PBM Capital的执行副总裁兼秘书，并于2018年开始在PBM Capital的法律部门担任越来越多的职责。在加入PBM Capital之前，Zawitz先生曾于2012年至2018年在CarMax，Inc.担任越来越多的职责，包括最近担任助理总法律顾问和助理秘书，并于2010年至2012年在Bingham McCutchen LLP和2007年至2009年在McKee Nelson LLP担任私人执业律师。Zawitz先生在弗吉尼亚大学获得了商业学士学位，专注于金融和信息技术，并在弗吉尼亚大学法学院获得了法学博士学位。他还是一名CFA包租人。
- David Zawitz,has served as Verrica Pharmaceuticals Inc. Chief Operating Officer since December 2024. He has also served as a consultant to PBM Capital since December 2024, after serving as Executive Vice President and Secretary of PBM Capital from March 2021 to December 2024 and following roles of increasing responsibility within PBM Capital's legal department beginning in 2018. Prior to joining PBM Capital, Mr. Zawitz served in roles of increasing responsibility with CarMax, Inc. from 2012 to 2018, including most recently as Assistant General Counsel and Assistant Secretary, and was an attorney in private practice with Bingham McCutchen LLP from 2010 to 2012 and McKee Nelson LLP from 2007 to 2009. Mr. Zawitz earned a B.S.C. in Commerce with concentrations in Finance and Information Technology from the University of Virginia and a J.D. from the University of Virginia School of Law. He is also a CFA charterholder.
- John J. Kirby
JohnJ.Kirby于2015年加入公司，担任公司会计Vice President，并于2018年7月至2019年7月担任财务Vice President，自2019年7月起担任高级副总裁兼首席财务官首席财务官自2018年10月起担任首席会计官。在加入我们之前，Kirby先生于2014年11月至2015年10月担任Endo Pharmaceuticals，Inc.的助理财务总监。2012年8月至2014年7月，Kirby先生担任Viropharma Incorporated的Vice President、首席会计官和公司财务总监，该公司于2014年1月被Shire plc收购。Kirby先生的职业生涯始于毕马威会计师事务所（KPMG，LLP）的梦百合和生命科学实践，并在加入Viropharma Incorporated之前担任阿斯利康制药公司（AstraZeneca Pharmaceuticals L.P.）的区域审计总监。Kirby先生在维拉诺瓦大学（Villanova University）获得会计学学士学位，是宾夕法尼亚州联邦的注册会计师。
John J. Kirby has served as the Chief Financial Officer of Idera since 2019. Mr. Kirby joined the Company in 2015 as Idera Pharmaceuticals, Inc. Vice President of Corporate Accounting. He served as Vice President of Finance from 2018 to 2019 and has served as Senior Vice President and Chief Financial Officer since 2019 (and as principal financial officer and principal accounting officer since 2018). Prior to joining Idera Pharmaceuticals, Inc. , Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from 2014 to 2015. From 2012 to 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated, which was acquired by Shire Plc in 2014. Mr. Kirby began his career at KPMG, LLP in its Healthcare and Life Science Practice and served as a Regional Audit Director at AstraZeneca Pharmaceuticals L.P. prior to joining ViroPharma Incorporated. Mr. Kirby received his B.S. in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania. Mr. Kirby has also served on the board of trustees of the Delaware Museum of Nature & Science (formerly the Delaware Museum of Natural History) since 2018.- JohnJ.Kirby于2015年加入公司，担任公司会计Vice President，并于2018年7月至2019年7月担任财务Vice President，自2019年7月起担任高级副总裁兼首席财务官首席财务官自2018年10月起担任首席会计官。在加入我们之前，Kirby先生于2014年11月至2015年10月担任Endo Pharmaceuticals，Inc.的助理财务总监。2012年8月至2014年7月，Kirby先生担任Viropharma Incorporated的Vice President、首席会计官和公司财务总监，该公司于2014年1月被Shire plc收购。Kirby先生的职业生涯始于毕马威会计师事务所（KPMG，LLP）的梦百合和生命科学实践，并在加入Viropharma Incorporated之前担任阿斯利康制药公司（AstraZeneca Pharmaceuticals L.P.）的区域审计总监。Kirby先生在维拉诺瓦大学（Villanova University）获得会计学学士学位，是宾夕法尼亚州联邦的注册会计师。
- John J. Kirby has served as the Chief Financial Officer of Idera since 2019. Mr. Kirby joined the Company in 2015 as Idera Pharmaceuticals, Inc. Vice President of Corporate Accounting. He served as Vice President of Finance from 2018 to 2019 and has served as Senior Vice President and Chief Financial Officer since 2019 (and as principal financial officer and principal accounting officer since 2018). Prior to joining Idera Pharmaceuticals, Inc. , Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from 2014 to 2015. From 2012 to 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated, which was acquired by Shire Plc in 2014. Mr. Kirby began his career at KPMG, LLP in its Healthcare and Life Science Practice and served as a Regional Audit Director at AstraZeneca Pharmaceuticals L.P. prior to joining ViroPharma Incorporated. Mr. Kirby received his B.S. in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania. Mr. Kirby has also served on the board of trustees of the Delaware Museum of Nature & Science (formerly the Delaware Museum of Natural History) since 2018.